Nasdaq
$0.5874▼ 0.74%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $607,791.59Shares out 1.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
38- 10.13Pre-market26.10.13 22:098-KKey event#●●●#●●●
Bluejay Diagnostics, Inc.Bullish
Bluejay Diagnostics has completed the establishment of a manufacturing site for its Symphony cartridges, fulfilling a critical contractual milestone with Toray Industries ahead of the October 23, 2026 deadline. This achievement enhances the company's supply-chain resilience and advances its progress toward regulatory submission and commercialization.…more
$0.5874-0.74%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6Pre-market26.10.06 22:048-KKey event
Bluejay Diagnostics, Inc.
Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study for the Symphony IL-6 sepsis diagnostic platform. The study includes 777 evaluable patients, and the company plans to use this data to support a future 510(k) regulatory submission to the FDA.…more
$0.5874-0.74%vs prev closeView filingShare - 9.8After-hours26.09.09 05:508-KKey event
Bluejay Diagnostics, Inc.
Bluejay Diagnostics entered into a distribution and strategic partnership agreement with Lovell Government Services on September 1, 2026, to access U.S. federal healthcare markets. Under the agreement, Lovell is granted exclusive distribution rights for federal procurement opportunities requiring SDVOSB status, such as those with the VA and DoD, to prepare for commercialization upon receiving necessary FDA clearance.…more
$0.5874-0.74%vs prev closeView filingShare
37 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 19:33#●●●#●●●
Bluejay Diagnostics Completes Manufacturing Site for Symphony Cartridges…more
Bluejay Diagnostics has completed the establishment of a manufacturing site for its Symphony cartridges, hitting a key contractual milestone. This achievement marks a significant step forward as the company progresses toward regulatory submission and potential commercialization.…more
$0.5874-0.74%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.6Pre-market26.10.06 22:05
●●●●●●●● ●●●●● ●●●●●●
Bluejay Diagnostics has released preliminary clinical data from its SYMON-II trial, which evaluates a biomarker for predicting mortality in sepsis patients. The company is still in the process of analyzing results and requires further regulatory authorization for market entry.…more
$0.5874-0.74%vs prev closeShareBenzinga - 10.6Pre-market26.10.06 19:36
●●●●●●●● ●●●●● ●●●●●●
Bluejay Diagnostics announced baseline clinical data from its SYMON-II study evaluating the IL-6 biomarker for 28-day mortality risk in sepsis patients. This milestone supports the company's progress toward regulatory submission for its Symphony diagnostic platform.…more
$0.5874-0.74%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report